Nachrichten zur Hims & Hers Health Inc. Aktie

Regulatory Crackdown Reshapes the Path for Hims & Hers

FDA warning letters and a Novo Nordisk lawsuit pressure Hims & Hers compounded weight-loss drug mod…

Is It Time To Reconsider Hims & Hers Health (HIMS) After The Recent Share Price Slump

This article is intended to help you assess whether Hims & Hers Health at around US$16.45 still offers value or…

Barclays Lowers its Price Target on Hims & Hers Health, Inc. (HIMS) to $25 and Keeps an Overweight Rating

On February 24, 2026, Barclays lowered its price target on Hims & Hers Health, Inc. (NYSE:HIMS) to $25 from $48…

Hims & Hers Health (HIMS) Leads as Most Shorted Stock Among Mid-to-Large Caps

Hims & Hers Health (HIMS) tops the list of most shorted stocks among mid-to-large-cap companies, with a significant 36.9% of…

Hims & Hers Slips as FDA Targets GLP-1 Compounders

Hims & Hers Health (HIMS, Financials) traded lower after the U.S. Food and Drug Administration said it sent warning letters…

Hims & Hers Health (HIMS) Faces High Short Interest Amid Sector Trends

Key Takeaways: Hims & Hers Health (HIMS) leads the healthcare sector in short interest at 36.90%, indicating…

Hims & Hers partner rebuffs plans to reintroduce Wegovy copy

According to industry media Endpoints, US online pharmacy Strive Pharmacy had plans to relaunch a generic copy of Novo Nordisk’s…

CI Investments Inc. Has $11.71 Million Position in Hims & Hers Health, Inc. $HIMS

CI Investments Inc. boosted its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by…

Canaccord Lowers Hims & Hers Health, Inc. (HIMS) Price Target Patent Amid Dispute and FDA Scrutiny

Hims & Hers Health, Inc. (NYSE:HIMS) ranks among the most shorted stocks to buy according to analysts. Following Novo Nordisk’s…

Canaccord Lowers Hims & Hers Health, Inc. (HIMS) Price Target Patent Amid Dispute and FDA Scrutiny

Hims & Hers Health, Inc. (NYSE:HIMS) ranks among the most shorted stocks to buy according to analysts. Following Novo Nordisk’s…

Hims & Hers (HIMS) Faces Setback as FDA Issues Warning Letters

Key Takeaways: Hims & Hers Health (HIMS) faces regulatory scrutiny from the FDA, impacting its product offerings.…

Hims & Hers back in red as FDA doubles down on GLP-1 compounders

Hims & Hers (HIMS) stock falls as the FDA send warning letters to telehealth firms that illegally market low-cost compounded…

Hims & Hers Health: Leaving GLP-1s Behind

Hims & Hers remains a Strong Buy at $16, with fair value estimated at $22 despite recent headwinds. Click here…

Can Hims & Hers Overcome the FDA’s GLP-1 Crackdown?

The U.S. Food and Drug Administration (FDA) cracked down on GLP-1 copycats in February 2026. Despite this and tighter margins,…

Hims partner Strive Pharmacy will reintroduce GLP-1 pill pulled from market

Strive Pharmacy plans to relaunch oral semaglutide despite Novo Nordisk lawsuit and regulatory scrutiny that forced partner Hims & Hers…

Hims & Hers Stock (+13%) : MS Conf Reassurance Sparks Short Squeeze

Hims & Hers, a direct-to-consumer telehealth platform, saw its stock aggressively bid up 13% following management commentary at a Morgan…

Hims & Hers Stock (HIMS) Surged 13.5% — Could More Gains Be Ahead?

Shares of Hims Hers Health ($HIMS) were up by 13.5% on Monday. The surge came after comments from Health…

Hims & Hers Health, Inc. (HIMS) Presents at Morgan Stanley Technology, Media & Telecom Conference 2026 Transcript

…

Insider Sell: Soleil Boughton Sells Shares of Hims & Hers Health Inc (HIMS)

On February 27, 2026, Soleil Boughton, Chief Legal Officer of Hims & Hers Health Inc (HIMS), sold 4,651 shares of…

Hims & Hers Health (NYSE:HIMS) Stock Price Up 10.5%

Hims & Hers Health (NYSE:HIMS) Stock Price Up 10.5% - Heres Why…

Hims & Hers surges after RFK Jr tells Joe Rogan he’s hoping to make peptides more accessible

Hims & Hers (HIMS) is spiking on Monday amid some remarks that Health and Human Services Secretary Robert F Kennedy…

Hims & Hers Surges on Strong Results and Strategic Acquisitions?

Hims & Hers Health Inc.’s stocks have been trading up by 10.3 percent due to investor optimism. Key Takeaways Revenue…

Why Hims & Hers Health (HIMS) Is Down 6.4% After New Shelf Filing And Regulatory Scrutiny

In late February 2026, Hims & Hers Health, Inc. reported past fourth-quarter 2025 sales of US$617.82 million and full-year 2025…

Hims And Hers Health Weighs Regulatory Pressure Against Growth And Valuation

Hims & Hers Health (NYSE:HIMS) has come under regulatory scrutiny over its weight loss drug offerings, drawing warnings from the…

Hims & Hers stock rises 3.93% as technical indicators show strong selling pressure

Hims & Hers rises 3.93% today to $15.09. Technicals point to persistent bearish pressure and limited upside in the near…

Analysis-Hims expansion may not come in time for risky GLP-1 business

By Amina Niasse NEW YORK, March 2 (Reuters) - Telehealth company Hims & Hers Health, known for its weight-loss drug…

Analysis-Hims expansion may not come in time for risky GLP-1 business

NEW YORK, March 2 (Reuters) - Telehealth company Hims & Hers Health, known for its weight-loss drug business, is promising…

A Look At Hims & Hers (HIMS) Valuation After Regulatory Setbacks And Softer Revenue Outlook

Hims & Hers Health (HIMS) is back in the spotlight after its Q4 2025 earnings per share beat, which contrasted…

Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know

Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise…

Hims Faces GLP-1 Scrutiny While Broader Telehealth Growth Story Evolving

Hims & Hers Health (NYSE:HIMS) is facing a patent infringement lawsuit from Novo Nordisk over its compounded weight loss drugs.…

Got $5,000? Hims & Hers Could Be a Direct?to?Consumer Health Moonshot in the Making

Hims & Hers is facing some well-deserved pushback from Novo Nordisk, but the big picture is still promising.…

Got $5,000? Hims & Hers Could Be a Direct?to?Consumer Health Moonshot in the Making

Hims & Hers is facing some well-deserved pushback from Novo Nordisk, but the big picture is still promising.…

Got $5,000? Hims & Hers Could Be a Direct?to?Consumer Health Moonshot in the Making

Key PointsHims & Hers offers direct-to-consumer healthcare in a digitally native manner.…

How Investors Are Reacting To Hims & Hers Health (HIMS) Softer GLP-1 Outlook And ESOP Share Offering

In late February 2026, Hims & Hers Health reported fourth-quarter 2025 results showing higher sales year on year but slightly…

Hims & Hers at the Crossroads: Navigating the ‘Regulatory Winter’ of 2026

Hims & Hers at the Crossroads: Navigating the ‘Regulatory Winter’ of 2026…

Hims & Hers stock steadies in premarket as Citi cuts target, SEC probe keeps GLP-1 risks in play

Hims & Hers Health shares rose 0.3% premarket after a 2.3% gain Wednesday, closing at $15.82.…

The Complicated Battle Between Novo Nordisk and Hims & Hers

When Novo Nordisk filed suit against Hims & Hers in early February, the case immediately drew attention as a high-stakes…

Hims & Hers: The Telehealth Growth Story Younger Investors Cant Afford to Ignore

How fast can Hims & Hers grow without selling GLP-1 drugs? Maybe a lot faster than you think.…

Hims & Hers: The Telehealth Growth Story Younger Investors Cant Afford to Ignore

How fast can Hims & Hers grow without selling GLP-1 drugs? Maybe a lot faster than you think.…

Hims & Hers: The Telehealth Growth Story Younger Investors Cant Afford to Ignore

Key PointsHims & Hers Health stock beat on earnings but suffered a steep sales slowdown in Q4.…

The Law Offices of Frank R. Cruz Announces Investigation of Hims & Hers Health, Inc. (HIMS) on Behalf of Investors

The Law Offices of Frank R. Cruz is investigating potential claims against the board of directors of Hims & Hers…

Hims And Hers Health Q4 Margin Compression Tests Bullish Growth Narratives

Hims & Hers Health (HIMS) has capped FY 2025 with fourth quarter revenue of US$617.8 million and basic EPS of…

Hims & Hers bullish on growth prospects even as it faces increasing regulatory scrutiny

Hims & Hers executives struck a confident tone about the companys growth prospects on Monday as it launches new specialties…

HIMS vs. AMWL: Which Telehealth Stock Is the Better Investment Now?

Hims & Hers and Amwell are taking different paths in telehealth, but which stock offers the stronger opportunity today? Lets…

Hims & Hers Health: The GLP-1 Party Is Over

Hims & Hers Health is facing existential risk as regulatory uncertainty and margin erosion undermine its growth narrative. Click here…

Hims & Hers Aktie: EBITDA-Ausblick enttäuscht - Kursziel halbiert!

New York (www.aktiencheck.de) - Hims & Hers-Aktienanalyse von Morgan Stanley:Der Analyst von Morgan Stanley, Craig Hettenbach, stuft die Aktie von…

Hims & Hers Aktie unter Druck: Gewinn über Erwartungen, schwacher Q1-Ausblick - jetzt kaufen nach Zahlen?

Frankfurt (www.aktiencheck.de) - Hims & Hers-Aktienanalyse von XTB:Jens Klatt, Marktanalyst bei XTB, nimmt die Aktie von Hims & Hers (ISIN:…

Hims And Hers Balances GLP 1 Scrutiny With Eucalyptus Expansion Plans

Novo Nordisk filed a lawsuit against Hims & Hers Health (NYSE:HIMS) over alleged patent infringement tied to compounded weight loss…

Hims & Hers Earnings Call Signals Growth Amid Risks

Hims & Hers Health, Inc. (($HIMS)) has held its Q4 earnings call. Read on for the main highlights of the…